You are here

Biomarker Breast Pap Test

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA173919-01A1
Agency Tracking Number: R43CA173919
Amount: $224,931.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
15807 CHAGALL TERR
NORTH POTOMAC, MD 20878-3461
United States
DUNS: 803596662
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: Yes
Principal Investigator
 INDIRA POOLA
 (301) 906-0032
 ipoola@silbiotech.com
Business Contact
 DONNA WILLIAMS
Phone: (301) 906-0032
Email: info@silbiotech.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): This Phase I research proposal is to investigate the feasibility of developing a novel Biomarker Breast PapTest for screening Nipple Aspirate Fluid (NAF) and detecting breast cancers at the tumor-in-formation stage before mammographically detectable tumors are developed. Although there is a slight decline in deaths from breast cancer in recent years, it continues to be the most diagnosed cancer and the second leading cause of cancer deaths for women in the USA. We canexpect a drastic reduction in the incidence and deaths if high risk women are identified before tumor formation and treated prophylactically. However, precise identification of high risk women for prophylactic measures has been a major clinical challenge.Currently, risk is assessed by Gail scoring and cytological examination of ductal cells in NAF elicited using NeOMatrix instrument (HALO Breast Pap Test). However, numerous studies have shown that cytology based risk assessment is highly subjective an

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government